Relationship Between The Efficacy Analysis Of 135 Cases Of Brain Glioma Patients And Their Molecular Markers

Objective: This study was performed to probe the relevant factors of the efficacy analysis about 135 cases of glioma patients, who were obtaining radiotherapy and chemotherapy after surgery, and its relationship with the protein expression of IDH1R132 gene mutation, MGMT, Ki-67 in human brain glioma tissues. It provided a more exactly method to diagnosis the malignancy of glioma, through detecting, the protein expression of IDH1R132 gene mutation, MGMT and Ki-67 jointly. What’ more, it provided a theoretical basis for individualized treatment of glioma.Method:Collecting 135 cases of glioma tissue sample, which were confirmed by surgical resection protein expression level of IDH1R132 gene mutation, MGMT and Ki-67 in tumor tissues were detected by streptavidin-peroxidase(SP) immunohistochemical staining method. We used SPSS13.0 statistical software to analyze the expression of IDH1R132 mutation, MGMT and Ki-67 protein in human glioma tissue, and used chi-square test to calculate the median survival time, survival rates, which was describing the corresponding survival curves and analysised by rog-rank analysis method.Results:1 Among 135 cases of glioma patients, the overall survival(OS) in patients, whose grades were Ⅱ, was relatively 91.8%, 88.5%, 77.5% in the first three years; there was73.9%, 40.8%, 13.6% relatively in patients with grade Ⅲ; and 46.2%, 38.5%relatively in patients with grade Ⅳin the first two years. There was no statistical significance on OS among the patients with different grades(P>0.05).2 In low level group(grade Ⅱ), in the first three years, the overall survival rates was 87.6%, 80.9%, 67.4% relatively in patients with radiotherapy along; it was 100%, 100%, 50% relatively in patients with radiotherapy and Nimusting; and 100%, 100%, 100%relatively in patients with radiotherapy and temozolomide. There was no statistical significance in patients with different treatment(P>0.05).3 In high level group(grade Ⅲ-Ⅳ), in the first three years, the overall survival rates was 67.5%, 31.3%, 0% relatively in patients with radiotherapy along; it was67.8%, 44.0%, 18.8% relatively in patients with radiotherapy and Nimusting; and69.8%, 40.7%, 40.7% relatively in patients with radiotherapy and temozolomide. There was no statistical significance in patients with different treatment(P>0.05).4 There were 42 cases with IDH1R132 mutation positive expression among 135 cases of glioma patients, whose overall positive rate was 31.1%. The median survival time was 30 months in patients with IDH1R132 mutation positive expression, negative for 17 months(P<0.01). There was statistical significance among patients with different grade about IDH1R132 mutation positive expression rate(P<0.05).5 There were 57 cases with MGMT positive expression among 135 cases of glioma patients, whose overall positive rate was 42.2%. The median survival time was 12 months in patients with MGMT positive expression, negative for 23 months(P<0.01). There was statistical significance among patients with different grade about MGMT positive expression rate(P>0.05).6 There were all of 135 cases of glioma patients with Ki-67 positive expression. There was no statistical significance among patients with different levels of Ki-67 positive expression(P>0.05). The expression level of Ki-67 positive was increasing along with grade increasing. It was statistical significance about Ki-67 positive expression among different grades glioma patients(P<0.05).Conclusions:1 The patients with different grades level through postoperative radiotherapy along or concurrent chemoradiotherapy had different prognosis, and the more grade level, the worse prognosis. But in the same grade level, the prognosis was no statistical significance with different treatment methods.2 Different grade levels had different IDH1R132 mutation positive expression rates, that is to say, IDH1R132 mutations expression had correlated with malignancy of glioma. What’s more, patients with IDH1R132 mutations expression got a better prognosis than without IDH1R132 mutation peers, and it had statistical significance.3 MGMT expression rate in patients with different grade levels varies, that is, the expression of MGMT was no correlation between the degree malignancy of glioma. The median survival time in patients with MGMT expression was shorter than the negative expression, and it had statistically significant, suggesting that without the expression of MGMT, patients had a better prognosis.4 There had the expression of Ki-67 among different grade levels of glioma. In addition, the expression level of Ki-67 positive was increasing along with grade increasing. The expression level of Ki-67 in grade Ⅲ-Ⅳ was higher than grade Ⅱ,and had statistical significance. However, the survival analysis showed that the level of Ki-67 expression has unrelated to diagnosis.